13:52 , Jun 29, 2017 |  BC Innovations  |  Translation in Brief

Tilt a flavin

A team from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and the University of Edinburgh has solved a problem that has stymied the development of kynurenine 3-monoxygenase (KMO) inhibitors -- the production of cytotoxic hydrogen peroxide -- and...
23:02 , Jun 27, 2017 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Structural analyses Structural analyses of P. fluorescens KMO bound to inhibitors could help guide the design of inhibitors of human KMO, which shares overall and active site sequence homology with the bacterial enzyme. The study...
08:00 , Feb 11, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Kynurenine 3-monoxygenase (KMO)

Gastrointestinal disease INDICATION: Pancreatitis Mouse and in vitro studies suggest inhibiting KMO could help treat pancreatitis. In a mouse model of acute pancreatitis, knockout of KMO decreased lung edema, kidney cell apoptosis and hepatocyte necrosis compared with...
08:00 , Feb 5, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Kynurenine 3-monoxygenase (KMO)

Neurology INDICATION: Huntington's disease (HD) In vitro and rat studies suggest novel KMO inhibitors could help treat HD. Patients with HD have elevated brain levels of quinolinic acid (QA) and 3-hydroxykynurenine (3-HK) - neurotoxic metabolites that are...
07:00 , Jul 14, 2011 |  BC Innovations  |  Cover Story

Gladstone's AD venture

The Gladstone Institute of Neurological Disease is launching a philanthropically funded translational research center to aid the preclinical development of Alzheimer's disease candidates emerging from the institute's research. The center hopes to pursue AD targets...
07:00 , Jun 30, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Kynurenine 3-monoxygenase (KMO) Studies in mice suggest small molecule antagonists of KMO could help...